Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits

BACKGROUND: Patients with locally advanced prostate cancer (LAPCa) received docetaxel-based neoadjuvant chemo-hormonal therapy (NCHT) had better clinical outcomes after surgery compared to neoadjuvant hormonal therapy (NHT) groups, but not all patients experienced favorable clinical outcomes with NC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yinjie, Fan, Liancheng, Zhu, Hanjing, Gong, Yiming, Chi, Chenfei, Wang, Yanqing, Pan, Jiahua, Dong, Baijun, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229793/
https://www.ncbi.nlm.nih.gov/pubmed/37265786
http://dx.doi.org/10.3389/fonc.2023.963411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229793/
https://www.ncbi.nlm.nih.gov/pubmed/37265786
http://dx.doi.org/10.3389/fonc.2023.963411

Ejemplares similares